Cited by 42HER2/EGFR in Cancer ResearchCell Adhesion Molecules ResearchCancer Cells and Metastasis

The Role of Multicellular Aggregation in the Survival of ErbB2-positive Breast Cancer Cells during Extracellular Matrix Detachment

Open access
Rayavarapu, Raju R., Heiden, Brendan, Pagani, Nicholas, Shaw, Melissa M., Shuff, Sydney, Zhang, Siyuan, Schafer, Zachary T.·2015·Journal of Biological Chemistry

Abstract

The metastasis of cancer cells from the site of the primary tumor to distant sites in the body represents the most deadly manifestation of cancer. In order for metastasis to occur, cancer cells need to evade anoikis, which is defined as apoptosis caused by loss of attachment to extracellular matrix (ECM). Signaling from ErbB2 has previously been linked to the evasion of anoikis in breast cancer cells but the precise molecular mechanisms by which ErbB2 blocks anoikis have yet to be unveiled. In this study, we have identified a novel mechanism by which anoikis is inhibited in ErbB2-expressing cells: multicellular aggregation during ECM-detachment. Our data demonstrate that disruption of aggregation in ErbB2-positive cells is sufficient to induce anoikis and that this anoikis inhibition is a result of aggregation-induced stabilization of EGFR and consequent ERK/MAPK survival signaling. Furthermore, these data suggest that ECM-detached ErbB2-expressing cells may be uniquely susceptible to targeted therapy against EGFR and that this sensitivity could be exploited for specific elimination of ECM-detached cancer cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m114.612754

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cancer cells need to acquire at least some degree of resistance to anoikis to initiate and progress through the metastatic cascade.

    “Accordingly, cancer cells need to acquire at least some degree of resistance to anoikis to initiate and progress though the so-called “metastatic cascade” [237–239].”
  • Neoplastic cells can evade anoikis upon activation of ERK2 caused by cellular aggregation and consequent EGFR stabilization mediated by ERBB2, or degradation of the negative ERK2 regulator BRAP, which is favored by CCDC178.

    “Neoplastic cells can evade anoikis upon activation of mitogen-activated protein kinase 1 (MAPK1; best known as ERK2) caused by cellular aggregation and consequent epidermal growth factor receptor (EGFR) stabilization mediated by erb-b2 receptor tyrosine kinase 2 (ERBB2) [237, 240], or degradation of the negative ERK2 regulator BRCA1-associated protein (BRAP), which is favored by coiled-coil domain”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rayavarapu, R. R., Heiden, B., Pagani, N., Shaw, M. M., Shuff, S., Zhang, S., & Schafer, Z. T.
Affiliations
University of Notre Dame (US)
Corresponding author
Schafer, Zachary T.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2015-04
Volume
290
Issue
14
Pages
8722-8733
ISSN
0021-9258 (ISSN-L)
OpenAlex
W1965349285
Cited by
42
References
54
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 12 · 2017: 3 · 2016: 4
FWCI
2.77
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (5R00CA158066)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
ERBB2, HER2-positive breast cancer, anoikis, extracellular matrix detachment, ERK signaling, tumor cell survival, metastasis, anti-EGFR therapy
MeSH terms
Breast Neoplasms, Extracellular Matrix, Female, Humans, Signal Transduction, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review